J Diabetes Investig. 2022 Jun 21. doi: 10.1111/jdi.13862. Online ahead of print.
OBJECTIVE: This study was conducted to assess the association of Dehydroepiandrosterone (DHEA) with diabetic nephropathy in patients with T2DM to better predict the progression of diabetic nephropathy.
METHODS: A total of 1082 patients with T2DM in the Department of Endocrinology and Metabolism of Tianjin Medical University General Hospital were inrolled in this study，and grouped for comparison.The effect of serum DHEA on DN was evaluated by multivariate Logistic regression analysis, and receiver operating characteristiccurves (ROC) were established to explore the optimal concentration of DHEA in patients with DN and non-DN.
RESULTS: DHEA was significantly decreased in patients with diabetic nephropathy (P < 0.001). The prevalence of diabetic nephropathy was significantly higher in the low DHEA quartile than in the other quartiles (P < 0.001).Spearman-related analysis showed that DHEA levels were negatively correlated with patient age, course of diabetes, systolic blood pressure, blood creatinine(Cr), uric acid(Ur), urine albumin-to-creatinine ratio (ACR), 24-hour urine microalbumin(24 h UMA), 24-hour urine protein quantification(24hUAER), and glomerular fltration rate(GFR), positively correlated with Body mass index (BMI) , total cholesterol(TC), and low density lipoprotein (LDL).Logistic regression analysis showed that the effect of DHEA on diabetic nephropathy was statistically significant (P< 0.001).The ROC curve showed that the sensitivity was 81.4%, the specificity was 70%, and the area under the curve was 0.812 when the optimal cut-off value was 1640 (pg/mL).
CONCLUSION: DHEA is significantly associated with DN and may be a protective factor for DN and is important for the prediction of DN.